Weekly MI Briefing — Keytruda

Week ending 26 Aug 2026

1. This week’s recurring question themes

Dosing and administration — ~3 PI questions, 21 responses

• “What’s the labeled regimen for adjuvant treatment in resected melanoma…?”
• “How is Keytruda administered—IV infusion time, required dilution/infusion rate guidance, and any premedication or flush instructions?”
• “If my labs show elevated AST/ALT…what labeled actions are recommended… and at what thresholds?”

Answers were generally substantive and closely aligned on the melanoma regimen: 200 mg IV every 3 weeks for up to 1 year, with several also citing the 400 mg every 6 weeks option. Administration answers consistently mention a 30-minute infusion but vary in completeness on dilution, rate, premedication, and flushing.

Interactions — 1 PI question, 7 responses

• “I’m on warfarin and starting Keytruda—are there labeled drug–drug interaction concerns with anticoagulants or CYP/P-gp substrates…?”

Responses consistently state that direct CYP/P-gp interactions are not expected, but answers vary in how they frame practical considerations such as INR monitoring.

Special populations/eligibility — 1 PI question, 7 responses

• “Who is not eligible for Keytruda…e.g., prior organ transplant, active autoimmune disease?”

Answers discuss hypersensitivity, autoimmune disease, transplant history, pregnancy, and inflammatory bowel disease, but do not consistently cover infection-related considerations.

Substitution/biosimilar and comparison questions — 5 brand questions, 35 responses Questions addressed pharmacy substitution, generic/biosimilar status, and comparisons with Opdivo and Tecentriq. The substitution and biosimilar questions generated repeated regional and regulatory caveats. Comparison answers were lengthy but frequently hedged and sometimes used “best,” “stronger,” or “more effective” language.

2. Where no consistent answer currently exists

Two MI-relevant inconsistencies were identified:

• Administration: For “How is Keytruda administered…?”, only 2 of 7 answer variants mentioned hypersensitivity/allergic-reaction considerations; 5 omitted them. Thus, a person asking this question today may receive different completeness depending on the assistant used.
• Eligibility: For “Who is not eligible for Keytruda…?”, infection risk was mentioned in 4 of 7 variants and omitted in 3. Coverage of this requested eligibility/avoidance topic is therefore inconsistent.

These are direct signals that a single, complete MI-approved response is not reliably represented in available AI answers.

3. Off-label and substitution questions

No explicit off-label-use or compounded-substitution question was captured this week, and there is no off_label or compounded signal in the provided data. This should be monitored rather than treated as evidence that demand is absent.

Substitution/biosimilar questions were clearly real and recurring (14 tagged responses across two questions), but answers were heavily hedged around country, formulary, pharmacy, and interchangeability rules. Excerpts repeatedly state substitution “can happen in some cases” but is “not always allowed or automatic.” This suggests the topic warrants a clearly jurisdiction-scoped SRD/FAQ. No answer reflects a clearly authoritative, stable position on the specific substitution scenario.

4. Trend across weeks

This is the second available week, so trend interpretation is limited. Volume increased from 60 to 70 responses, while distinct questions remained at 10. Inconsistency flags decreased from 3 to 2, but administration and eligibility inconsistencies remain recurring priorities.

Hedging increased from 50 to 58 and overclaim language from 15 to 23. Biosimilar/generic tagging increased from 13 to 14, and dosing-specific tagging from 15 to 17. These indicate sustained demand for practical MI answers rather than a one-off spike.

5. Recommended actions

1. Update or create an administration SRD covering infusion duration, preparation/dilution, rate, flush, and premedication/hypersensitivity language. Priority: highest—7 responses and a 2-versus-5 completeness split. Currency/completeness review of existing content first; create a new SRD if no consolidated document exists.

2. Create or update an eligibility/special-populations SRD distinguishing true contraindications from situations requiring individualized assessment, including transplant, autoimmune disease, pregnancy, IBD, and infection-related considerations. Priority: high—7 responses and inconsistent infection coverage.

3. Create/update a jurisdiction-specific biosimilar/substitution FAQ/SRD addressing generic versus biosimilar terminology, interchangeability, and pharmacy substitution. Priority: high—two recurring questions and 14 tagged responses; monitor for compounded questions.

4. Review the comparative-information response for Keytruda versus Opdivo/Tecentriq and “more effective” claims, ensuring a clear, non-promotional MI answer grounded in indication, labeling, and evidence limitations. Priority: moderate—21 responses, but no cross-response inconsistency flag.

5. No new off-label or compounded SRD this week; monitor for recurrence before prioritizing document creation.